China’s mRNA vaccine makes slow pr • Table.Briefings

Arcov is China’s greatest hope in the battle against Covid. But there is still a long way to go before this new vaccine is ready for deployment. China’s borders will not be opened anytime soon, even with an mRNA vaccine.

On January 24, new data was published from a Phase 1 clinical trial of Arcov, China’s most advanced mRNA vaccine candidate (China.Table reported). According to the data, „high concentrations of neutralizing antibodies against live SARS-CoV-2“ were found in most subjects after two vaccinations. No severe side effects were recorded. However, the scientists also stated that it is still too early to accurately assess its efficacy.

China’s mRNA vaccine makes slow progress

Sign up now and continue reading immediately